Quantcast

Latest Ketones Stories

2014-10-31 08:26:34

LA JOLLA, Calif., Oct. 31, 2014 /PRNewswire/ -- Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center. Details on the presentation times are as follows: Date/Time: November 6, 2014,...

2014-10-30 20:23:31

- Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) TOKYO, Oct. 30, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA(TM) (edoxaban) 60 mg dosing...

2014-10-30 08:35:33

SAN DIEGO, Oct. 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may...

2014-10-29 08:33:42

WAYNE, Pa., Oct. 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its third quarter financial results will be released on Wednesday, November 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Egalet's website....

2014-10-28 23:03:07

Topical research study “Methyl Ethyl Ketone (MEK): 2014 World Market Outlook and Forecast up to 2018” elaborated by Merchant Research & Consulting Ltd is now available at mcgroup.co.uk. According to the report, the global demand for methyl ethyl ketone is poised to see positive growth through 2018. London, UK (PRWEB) October 28, 2014 Methyl ethyl ketone (MEK) is primarily utilised in the production of various coatings and solvents. Besides, this material finds application in the...

2014-10-28 08:36:58

WAISMANN METHOD® Medical Director Recognizes Patient Trend and Suggests Strategies to Address Potential Dependency Issues ORANGE, Calif., Oct. 28, 2014 /PRNewswire/ -- New data suggests the U.S. Drug Enforcement Agency's crackdown on Hydrocodone prescriptions has positively affected painkiller-related deaths, with a 5 percent decrease. However, according to a study by the Centers for Disease Control and Prevention (CDC), heroin deaths have doubled in the past two years, leading...

2014-10-28 08:34:53

Complementary to BUNAVAIL(TM); Potential to Leverage Current Addiction Sales Force RALEIGH, N.C., Oct. 28, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection....

2014-10-27 16:28:51

- Henrico County Sheriff's Office to Receive First Donation - RICHMOND, Va., Oct. 27, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced a new donation program that will allow qualifying local law enforcement agencies to receive EVZIO(TM) naloxone auto-injectors without charge as part of the kaleo Cares program. EVZIO, approved by the U.S. Food and Drug Administration (FDA) on April 3, 2014, is an opioid antagonist...

2014-10-27 08:29:30

CUPERTINO, Calif., Oct. 27, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY(®) (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory...

2014-10-23 16:25:56

Entrenchment of Current Analgesics and Increasing Cost Sensitivity Will Hamper Uptake of Emerging Acute Pain Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 23, 2014 /PRNewswire/ -- Decision Resources Group finds that the acute pain market will grow minimally from $12.7 billion in 2013 to $13.3 billion in 2023 across the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan), representing an annual...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related